CDKN2A and neoplasm: This wide range of published p16 positivity rates makes it difficult to assess the potential significance of p16 immunohistochemistry in individual tumor entities and may also be responsible for conflicting data on the potential prognostic and diagnostic relevance of p16 expression in such tumor entities.